With September being a textbook example of yet another buy-the-dip opportunity, and a move from the “lower left to the upper right” on the chart, are there any compelling investment ideas out there that may have flown under your radar? Below is a list of September Buy recommendations made by analysts who had no other bullish recommendations over the past 3 months. For your directory assistance, we've classified the opportunities by sector. Healthcare Capricor Therapeutics (CAPR) - Growth investor ...

Core Thesis - The Cigna Group is viewed as a compelling investment opportunity due to its strong fundamentals and tactical "buy-the-dip" setup following a nearly 12% decline in share price from June highs [2][6]. Financial Performance - Cigna's share price was $293.76 as of September 18th, with trailing and forward P/E ratios of 16.26 and 9.13 respectively [1]. - The company is experiencing mid-single-digit revenue and EPS growth, with a net margin of approximately 4.5%, which exceeds the managed-care average [2]. - Cigna maintains robust free cash flow supported by modest leverage, indicating financial stability [2]. Valuation and Market Position - The stock is valued at around 15 times forward EPS, slightly below peers despite higher return on equity (ROE) and superior cash conversion, suggesting it is fundamentally attractive [3]. - The stock trades below major moving averages, indicating a bearish bias, but momentum indicators suggest potential near-term relief [4]. Technical Analysis - Key support levels are identified around $285–280, with protective stops near $270, while resistance is mapped at $305–312 [4]. - A sustained recovery above the 100- and 200-day simple moving averages (SMAs) could lead to a medium-term price range of $320–340 [4]. Investment Strategy - A disciplined trade plan involves scaling into weakness, targeting a relief bounce followed by longer-term upside based on stable fundamentals [5]. - Cigna is positioned as a buy-on-weakness opportunity, with valuation, cash flow strength, and upcoming earnings acting as pivotal drivers for a potential rerating [5].

Core Viewpoint - AutoZone's Q4 earnings report indicates a stable performance amidst macroeconomic challenges, with share buybacks significantly contributing to stock price gains and a bullish outlook for future growth [1][2][10]. Financial Performance - AutoZone reported Q4 revenue of $6.24 billion, reflecting a 0.5% increase year-over-year, which adjusts to a 6.9% growth when accounting for an extra week in the fiscal year [6]. - The company experienced a decline in net income to $837 million, with GAAP EPS at $48.71, but maintained a buyback ratio of approximately 53% [7]. Share Buybacks - The company reduced its share count by nearly 2% year-over-year in Q4 and by 3.2% for the year, enhancing leverage for investors [2]. - Persistent buyback activity has led to a shareholder deficit on the balance sheet, but this is overshadowed by its positive impact on stock price and cash flow [3]. Asset Management - At the close of fiscal 2025, AutoZone's cash declined by 8.8%, but this was offset by a $1 billion increase in current assets and a $2.2 billion increase in total assets, alongside a reduction in debt [4]. Growth Strategy - The company is accelerating store count openings and increasing inventory, which is expected to support future growth despite current margin pressures [3][8]. - Analysts forecast mid-single-digit revenue growth in 2026, with earnings expected to grow at an accelerated mid-teens pace [9]. Analyst Sentiment - AutoZone stock has a consensus Moderate Buy rating from 25 analysts, with a price target of $4,449.18, indicating a potential upside of 7.64% [10]. - The stock is projected to reach a new all-time high, with a high-end forecast of $4,925, representing a 20% upside [11].

We couldn't break the resistance for #Bitcoin, and therefore we're correcting back down.I'm not sure if this is it, given the heavy wick on #Altcoins. I would say so, at least, we're scanning for a potential massive buy-the-dip opportunity on the markets before the up-only season. ...

Core Insights - Abercrombie & Fitch (ANF) and PVH are set to report their Q2 results, attracting investor interest as potential buy-the-dip candidates due to a possible rate cut in September [1][2] Q2 Expectations - Abercrombie & Fitch is expected to report a nearly 5% year-over-year sales increase to $1.19 billion, but earnings per share (EPS) are projected to decline by 9% to $2.27 [4] - PVH's Q2 sales are anticipated to rise by 1% to $2.1 billion, while EPS is expected to drop over 34% to $1.97 [6] Performance History - Abercrombie & Fitch has surpassed sales expectations for 11 consecutive quarters and has exceeded the Zacks EPS Consensus for nine straight quarters, with an average earnings surprise of 11.24% [4][8] - PVH has exceeded sales estimates for six straight quarters and has surpassed the Zacks EPS Consensus for 17 consecutive quarters, with an average earnings surprise of 13.47% [8] Valuation Metrics - Both ANF and PVH stocks are trading under 10 times forward earnings and below 2 times sales, earning an "A" Zacks Style Scores grade for Value [10] Investment Outlook - The upcoming Q2 reports and guidance for both companies will be critical for determining potential upside, with both currently holding a Zacks Rank 3 (Hold) [12]

Market Sentiment - ETF 抛售通常是最佳的逢低买入时机 [1] - ETH (以太坊) 仍然被低估 [1]

Core Viewpoint - Eli Lilly's stock experienced a significant decline despite strong Q2 earnings, primarily due to disappointing clinical trial data for its weight loss drug orforglipron, which has raised concerns about its market potential and competitive position against Novo Nordisk [1][2][10]. Financial Performance - Eli Lilly reported Q2 sales of $15.6 billion, marking a 38% increase year-over-year, and adjusted earnings per share (EPS) rose by 61% to $6.31, surpassing Wall Street estimates [3][4]. - The company increased its full-year 2025 guidance by $1.5 billion at the midpoint, indicating strong overall performance despite the stock drop [4]. Market Position and Competition - Eli Lilly gained 3.8% market share in the U.S. weight loss drug market, continuing to lead over Novo Nordisk [4]. - The disappointing results from the orforglipron clinical trials have raised concerns about Eli Lilly's ability to maintain its competitive edge, especially as Novo Nordisk's oral GLP-1 drug has shown better efficacy [9][10]. Clinical Trial Data - Orforglipron's Phase 3 ATTAIN-1 results indicated an average weight loss of 11.5% at 72 weeks, which is below the previous findings of 12.4% at 36 weeks and also lower than Novo Nordisk's 12.7% at 68 weeks [7][9]. - The market's reaction to the orforglipron data suggests a significant disappointment, impacting investor sentiment and stock performance [10]. Future Outlook - Despite the current challenges, there is potential for orforglipron to tap into a new patient demographic that prefers oral medications over injectables, which could still provide growth opportunities for Eli Lilly [12][14]. - Eli Lilly plans to submit orforglipron for regulatory approval by the end of 2025, with potential sales starting in 2026, although competition from Novo Nordisk's oral GLP-1 could pose risks [13][14]. Investment Considerations - The recent stock decline may present a buy-the-dip opportunity, as analysts maintain a Moderate Buy rating with a 12-month price target of $999.50, indicating a potential upside of 58.77% [8][15].

Core Viewpoint - Pool Corp. is facing a challenging economic environment, with its stock down approximately 12% year to date, but this may present a buying opportunity for investors as it is a high-quality industry leader available at a discount [1]. Group 1: Company Overview - Pool Corp. is the world's largest pool supplies distributor, operating 448 sales centers across North America, Europe, and Australia, serving over 125,000 customers [5]. - The company owns the Pinch A Penny retail franchise, which has around 300 locations [5]. - Pool Corp.'s revenue is significantly driven by recurring sales, with 86% coming from consistent upkeep products for installed pools [6]. Group 2: Financial Performance - Over the past five years, Pool Corp. has achieved a 14% compound annual growth rate (CAGR) in total revenue, reaching $5.3 billion in 2024 [8]. - Despite a slowdown in new pool construction, management remains optimistic about growth from its expanding private-label business and the Pool360 digital platform [9][10]. - For 2025, Pool Corp. anticipates net sales to be "flat to slightly higher" year over year, with an earnings-per-share (EPS) estimate of $11.08 to $11.58, indicating a 3% increase at the midpoint compared to 2024 [10]. Group 3: Capital Allocation and Shareholder Returns - Pool Corp. has a strong free cash flow generation, allowing for a generous capital allocation strategy, including a recent 4% increase in its quarterly dividend to $1.25 per share, yielding about 1.3% [11]. - The company has also increased its share repurchase authorization to $600 million, demonstrating its commitment to shareholders [11]. Group 4: Valuation and Market Position - Pool Corp.'s current forward price-to-earnings (P/E) ratio is 27, which is a discount compared to its historical average P/E of around 30 over the past decade, suggesting the stock may be undervalued [12]. - A potential recovery in the housing market and pool construction, aided by subdued inflation and lower interest rates, could enhance company performance [14].

Core Viewpoint - FedEx reported strong fiscal Q4 results but saw its stock decline by 3%, impacting UPS shares as well [1][2] FedEx Q4 Results - FedEx's Q4 earnings increased by 12% to $6.07 per share, exceeding EPS estimates of $5.93 [3] - Q4 sales reached $22.22 billion, surpassing estimates of $21.73 billion and slightly up from $22.1 billion in the same quarter last year [3] - FedEx has missed the Zacks EPS Consensus in two of the last four quarters, with an average EPS surprise of -5.53% [4] UPS Q2 Expectations - UPS's Q2 sales are projected to decline by 4% to $20.84 billion compared to $21.82 billion a year ago [5] - Expected Q2 EPS for UPS is forecasted to fall by 12% to $1.57 from $1.79 in the prior year quarter [5] - UPS has exceeded earnings expectations in three of its last four quarterly reports, with an average EPS surprise of 2.42% [6] Performance & Valuation Comparison - Both FedEx and UPS stocks are down 20% this year, but FedEx has a total return of +86% over the last five years, outperforming UPS's +11% [7] - FedEx and UPS have lower P/E valuations at 11.7X and 14.2X forward earnings, respectively, compared to the S&P 500's 23.5X [8] Dividend Comparison - UPS currently offers a higher annual dividend yield of 6.52%, compared to FedEx's 2.41% and the S&P 500's average of 1.22% [10] Bottom Line - FedEx and UPS are considered appealing buy-the-dip targets in terms of value, with FedEx potentially being the better long-term pick despite UPS's attractive dividend [11]

Core Viewpoint - AppLovin Corporation (APP) has experienced a significant stock increase of over 700% in 2024, driven by strong earnings and revenue growth, but faced recent pressure from short-seller allegations of misleading advertising practices, which the CEO has denied [1][12] Financial Performance - In Q4 2024, AppLovin's revenues increased by 44% year-over-year and 14% sequentially, with adjusted EBITDA rising by 78% year-over-year and 17.5% sequentially, indicating improved operational efficiency [7] - For the full year 2024, revenues climbed 43% year-over-year, while adjusted EBITDA surged 81%, showcasing the company's ability to capitalize on market opportunities [8] - The company has guided for $1.4 billion in sales for Q1 2025, slightly above the Zacks Consensus Estimate of $1.37 billion, with a history of beating earnings expectations [8] Analyst Projections - The Zacks Consensus Estimate for Q1 2025 earnings is projected at $1.45 per share, reflecting a 116.4% year-over-year increase, with expected earnings growth of 51.7% and 37.1% for 2025 and 2026, respectively [9] - Over the past 60 days, there have been multiple upward revisions in earnings estimates for Q1 2025 and for 2025 overall, indicating strong analyst confidence in AppLovin's growth potential [10] Strategic Shift - AppLovin is transitioning into a pure-play advertising platform, focusing on high-growth, high-margin segments, exemplified by the $900 million sale of its gaming unit to Tripledot Studios, allowing for a concentrated effort on ad technology [6] - The company aims to serve the global digital advertising market, which includes over 10 million businesses, by investing in automation and developing advanced tools to enhance customer efficiency and maximize ad performance [6] Competitive Landscape - Competitors in the in-game mobile advertising space, such as Alphabet Inc. (GOOGL) and Meta Platforms (META), have also seen declines of 11% and 14% respectively in the past month, suggesting that AppLovin's recent stock performance may be part of a broader industry trend [4]